

## Electronic Supplementary Information

### Targeted doxorubicin delivery to hepatocarcinoma cells by lactobionic acid-modified laponite nanodisks †

*Guangxiang Chen<sup>1</sup>, Du Li<sup>2</sup>, Jingchao Li<sup>1</sup>, Xueyan Cao<sup>1</sup>, Jianhua Wang<sup>3\*</sup>, Xiangyang Shi<sup>1,2\*</sup>, Rui Guo<sup>1\*</sup>*


<sup>1</sup> *College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, People's Republic of China.*

<sup>2</sup> *College of Materials Science and Engineering, Donghua University, Shanghai 201620, People's Republic of China.*


<sup>3</sup> *Department of Biochemistry and Molecular & Cell Biology, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, People's Republic of China*

**Table S1.** Zeta Potential and Hydrodynamic Diameter of LM-*m*PEG and LM-PEG-LA in PBS buffer (pH=7.4).


Sample	Zeta Potential (mV)	Hydrodynamic Diameter (nm)
LM- <i>m</i> PEG	-14.5 ± 1.4	357.7 ± 12.6
LM-PEG-LA	-14.4 ± 1.3	337.9 ± 13.1




**Figure S1.** FTIR spectra of (a) LM-NH<sub>2</sub>, LM-*m*PEG and *m*PEG.




**Figure S2.** MTT assay of HepG2 cell viability after treatment with LM-*m*PEG and LM-PEG-LA at the concentration of 0-64 µg/mL for 24 h.



**Fig. S3** Micrographs of HepG2 cells without treatment (a) and HepG2 cells treated with LM-mPEG (b), LM-PEG-LA (c), LM-mPEG/DOX (d), LM-PEG-LA/DOX (e), and free DOX (f) at the same DOX concentration of 2  $\mu\text{g}/\text{mL}$  for 24 h, respectively.



**Fig. S4** CLSM images of MCF-7 cells treated with PBS (a), free DOX(b), LM-mPEG/DOX (c), LM-PEG-LA/DOX (d) with a DOX concentration of 2  $\mu\text{g}/\text{mL}$  for 4 h at 37  $^{\circ}\text{C}$ .



**Fig. S5** FCM analysis of HepG2 cells or MCF-7 cells treated with PBS (a), free DOX (b), LM-*m*PEG/DOX (c) and LM-PEG-LA/DOX (d) in at a DOX concentration of 2  $\mu$ g/mL for 4 h.